Dr. Heinemann Reviews the FIRE-3 Trial Results

Volker Heinemann, MD, PhD
Published: Sunday, Jun 02, 2013

Volker Heinemann, MD, PhD, a professor of medical oncology at the University of Munich in Munich, Germany, discusses results from the phase III FIRE-3 trial that looked at FOLFIRI plus bevacizumab or cetuximab as a first-line treatment for patients with wild-type KRAS metastatic colorectal cancer.

In the trial, the objective response rate (ORR) was comparable between the two treatments (bevacizumab and cetuximab). However, in patients who received at least 3 cycles of treatment and had one imaging procedure after baseline, a 10% ORR benefit was observed in the cetuximab arm, Heinemann notes.

Read more about this study >>>

<<< View more from the 2013 ASCO Annual Meeting

Volker Heinemann, MD, PhD, a professor of medical oncology at the University of Munich in Munich, Germany, discusses results from the phase III FIRE-3 trial that looked at FOLFIRI plus bevacizumab or cetuximab as a first-line treatment for patients with wild-type KRAS metastatic colorectal cancer.

In the trial, the objective response rate (ORR) was comparable between the two treatments (bevacizumab and cetuximab). However, in patients who received at least 3 cycles of treatment and had one imaging procedure after baseline, a 10% ORR benefit was observed in the cetuximab arm, Heinemann notes.

Read more about this study >>>

<<< View more from the 2013 ASCO Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x